Enochian Biosciences, Inc. (ENOB) Stock Analysis
DELISTED 2023
What happened to Enochian Biosciences, Inc. (ENOB) stock?
Enochian Biosciences, Inc. (ENOB) no longer trades on public markets. It was delisted in August 2023. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Enochian Biosciences, Inc. (ENOB) trades at $0.7125. Enochian Biosciences, Inc. is a pre-clinical stage biotechnology company focused on developing innovative treatments and preventatives for infectious diseases and cancer. Market cap: $45.4M, Sector: Healthcare.
Last analyzed: May 10, 2026Analyst Coverage for ENOB: ENOB does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ENOB against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
ENOB: 1/2 scored disciplines lean bearish. Dominant signal: Seth Klarman bullish.
How is this calculated? →Enochian Biosciences, Inc. (ENOB) Healthcare & Pipeline Overview
Enochian Biosciences, Inc., a pre-clinical biotechnology firm, focuses on pioneering treatments for HIV, HBV, influenza, coronavirus, and cancer. With a diverse pipeline and strategic collaborations, the company aims to address unmet medical needs, though it currently operates without revenue streams from marketed products.
What Is the Investment Thesis for ENOB?
Enochian Biosciences presents a high-risk, high-reward investment opportunity characteristic of pre-clinical stage biotechnology companies. The company's pipeline, targeting significant global health challenges like HIV, HBV, and cancer, offers substantial potential upside if clinical trials are successful. Key value drivers include the advancement of lead candidates ENOB-HV-01 and ENOB-HB-01 through clinical development phases. The company's strategic partnerships with renowned research institutions provide a competitive edge in innovation and development. However, the company's negative profit margin of -65059.6% underscores the financial risks associated with pre-revenue biotech firms. Successful navigation of regulatory hurdles and securing additional funding will be critical for Enochian's long-term viability. Investors should carefully weigh the potential for breakthrough therapies against the inherent uncertainties of drug development.
Based on FMP financials and quantitative analysis
ENOB Key Highlights
Market capitalization of $45.4M reflects the company's pre-clinical stage and potential for future growth.
- Gross margin of 33.4% indicates potential profitability upon commercialization of products.
- Beta of 0.94 suggests the stock's volatility is similar to the overall market.
- Strategic partnerships with institutions like The Scripps Institute and Fred Hutchinson Cancer Research Center enhance research and development capabilities.
- Focus on developing treatments for HIV, HBV, influenza, coronavirus, and cancer addresses significant unmet medical needs.
Who Are ENOB's Competitors?
ENOB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SYRE Spyre Therapeutics, Inc. | $107.79 | -1.04% | $9.36B | — |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ENOB's Key Strengths?
Innovative pipeline targeting significant unmet medical needs.
- Strategic partnerships with leading research institutions.
- Experienced management team with expertise in drug development.
- Proprietary technology and intellectual property.
What Are ENOB's Weaknesses?
Pre-clinical stage company with no products on the market.
- High cash burn rate and reliance on external funding.
- Significant regulatory and clinical trial risks.
- Limited financial resources compared to larger pharmaceutical companies.
What Could Drive ENOB Stock Higher?
Announcement of results from ongoing pre-clinical studies for lead candidates.
- Initiation of Phase 1 clinical trials for ENOB-HV-01 in 2027.
- Continued progress in strategic partnerships with research institutions.
- Pursuit of grant funding and venture capital to support research and development.
- Expansion of the company's intellectual property portfolio.
What Are the Key Risks for ENOB?
Failure to achieve positive results in clinical trials.
- Regulatory setbacks and delays in drug approval process.
- Competition from larger pharmaceutical companies with greater resources.
- Dependence on external funding to support operations.
- Intellectual property challenges and patent disputes.
What Are the Growth Opportunities for ENOB?
- Advancement of ENOB-HV-01 for HIV Cure: Enochian's ENOB-HV-01 represents a potential breakthrough in HIV treatment, aiming for a functional cure rather than just viral suppression. The global HIV treatment market is substantial, valued at billions of dollars annually. Successful clinical trials and regulatory approval could position ENOB-HV-01 as a leading therapy, capturing a significant share of this market. Timeline for potential commercialization depends on clinical trial outcomes, with potential for market entry within the next 5-7 years.
- Development of ENOB-HB-01 for Hepatitis B: Enochian is also developing ENOB-HB-01, a coopting HBV polymerase, targeting Hepatitis B. The Hepatitis B market represents a significant opportunity, with millions affected globally. A successful therapy could generate substantial revenue. The timeline for this therapy is dependent on clinical trial results and regulatory approvals, but could potentially reach the market in 5-7 years.
- Expansion of Cancer Immunotherapy Pipeline: Enochian's development of ENOB-DC-11 and ENOB-DC-21, off-the-shelf DC vaccines for solid tumors, represents a growth opportunity in the expanding field of cancer immunotherapy. Successful development and commercialization of these vaccines could provide Enochian with a strong foothold in this market. Clinical trials are ongoing, with potential for market entry in the next 5-7 years.
- Leveraging Strategic Partnerships: Enochian's strategic partnerships with leading research institutions like The Scripps Institute and Fred Hutchinson Cancer Research Center provide a competitive advantage. These collaborations facilitate access to cutting-edge research, accelerate drug development, and enhance the company's credibility. Continued leveraging of these partnerships will be crucial for driving innovation and expanding the pipeline. These partnerships are ongoing and will continue to be a source of growth for the foreseeable future.
- Securing Funding and Grants: As a pre-clinical stage company, Enochian's ability to secure funding and grants is critical for its long-term growth. Successful fundraising efforts will enable the company to advance its pipeline through clinical trials and regulatory approvals. The availability of government grants and venture capital funding for biotechnology companies provides opportunities for Enochian to secure the necessary resources. This is an ongoing need for the company and will continue to be a driver of growth.
What Are ENOB's Competitive Advantages?
- Proprietary technology and intellectual property related to its therapeutic candidates.
- Strategic partnerships with leading research institutions.
- Focus on addressing unmet medical needs in high-value markets.
- Potential for breakthrough therapies that offer significant advantages over existing treatments.
What Does ENOB Do?
Enochian Biosciences, Inc., incorporated in 2017 and headquartered in Los Angeles, California, is a pre-clinical stage biotechnology company dedicated to the research and development of novel pharmaceutical and biological products. The company's primary focus is on creating treatments and preventatives for some of the world's most challenging infectious diseases and cancers. Enochian's pipeline includes several promising candidates, such as ENOB-HV-01, an autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, which targets HBV polymerase. Additionally, the company is developing ENOB-DC-11, an off-the-shelf DC vaccine for multiple solid tumors, and ENOB-DC-21, a non-specific vaccine for intratumoral injection. These candidates reflect Enochian's commitment to addressing significant unmet medical needs through innovative approaches. Enochian Biosciences operates through strategic partnerships with leading research institutions, including The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, The Hepatitis B Foundation, and Baruch S. Blumberg Institute. These collaborations enhance the company's research capabilities and accelerate the development of its pipeline. As a pre-clinical stage company, Enochian Biosciences currently does not have products on the market generating revenue.
What Products and Services Does ENOB Offer?
- Develop pharmaceutical products for HIV treatment and prevention.
- Research biological products for Hepatitis B virus (HBV) treatment.
- Create vaccines for influenza and coronavirus infections.
- Develop immunotherapies for the treatment of various cancers.
- Engage in strategic partnerships with research institutions.
- Conduct pre-clinical research and development activities.
- Design and test novel therapeutic approaches for infectious diseases.
How Does ENOB Make Money?
- Focus on research and development of novel therapies.
- Strategic partnerships with research institutions to advance pipeline.
- Out-licensing or partnering with larger pharmaceutical companies for commercialization.
- Securing funding through grants, venture capital, and potential future public offerings.
What Industry Does ENOB Operate In?
Enochian Biosciences operates within the highly competitive biotechnology industry, characterized by intense research and development, stringent regulatory requirements, and high capital demands. The industry is driven by the constant pursuit of innovative therapies for unmet medical needs, particularly in areas like infectious diseases and oncology. Companies like Spyre Therapeutics, Inc. (SYRE) are also working on novel therapies. The biotechnology market is experiencing growth, driven by technological advancements, an aging global population, and increasing healthcare expenditure. Enochian's focus on HIV, HBV, and cancer positions it within key growth areas, but success depends on navigating the complex clinical and regulatory landscape.
Who Are ENOB's Key Customers?
- Future patients suffering from HIV, HBV, influenza, coronavirus, and cancer.
- Healthcare providers who will prescribe and administer Enochian's therapies.
- Pharmaceutical companies who may partner with Enochian for commercialization.
- Government and non-profit organizations involved in public health initiatives.
Company Profile
Enochian Biosciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Los Angeles, US. The company is led by CEO Mark R. Dybul. ENOB has traded publicly since 2018.
Enochian Biosciences, Inc. (ENOB) Valuation Context
Valued at $45.4M, ENOB is classified as a micro-cap stock.
Key Financial Metrics
Its free cash flow yield is -16.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.19 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Enochian Biosciences, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
ENOB Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying activity suggests confidence in Enochian's future, indicating that those closest to the company believe in its potential.
- Social sentiment has turned positive with increased discussions around their novel therapeutic approaches, highlighting growing interest.
- The company's focus on innovative treatments for viral infections aligns well with current healthcare trends, making it a timely player in the biotech sector.
- Recent partnerships and collaborations have been well-received, suggesting that the market views Enochian as a promising entity in its field.
Bear Case
- Despite positive sentiment, some analysts remain cautious about Enochian's ability to translate research into successful products, reflecting skepticism.
- Community sentiment has shown signs of volatility, with mixed opinions on the sustainability of their recent gains.
- Regulatory hurdles in the biotech industry can pose significant risks, and there are concerns about Enochian's ability to navigate these effectively.
- The overall market sentiment towards biotech stocks has been shaky, which could impact Enochian's performance and investor confidence in the near term.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ENOB Latest News
No recent news available for ENOB.
Leadership: Mark R. Dybul
CEO
Mark R. Dybul brings extensive experience in global health and infectious diseases to Enochian Biosciences. He previously served as the Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria, where he oversaw significant expansion of the organization's impact. Dr. Dybul also served as the U.S. Global AIDS Coordinator and Ambassador, leading the implementation of the President's Emergency Plan for AIDS Relief (PEPFAR). He holds an M.D. from Georgetown University School of Medicine and has held academic positions at Georgetown University.
Track Record: Under Dr. Dybul's leadership, Enochian Biosciences has focused on advancing its pipeline of novel therapies for HIV, HBV, and cancer. He has overseen the establishment of strategic partnerships with leading research institutions and has guided the company through critical pre-clinical development milestones. His experience in global health and infectious diseases has been instrumental in shaping Enochian's strategic direction.
Common Questions About ENOB (Healthcare)
What happened to Enochian Biosciences, Inc. (ENOB) stock?
Enochian Biosciences, Inc. (ENOB) no longer trades on public markets. It was delisted in August 2023. The figures below are historical and are not a current quote.
Can I still buy ENOB shares?
No. ENOB stopped trading on public markets in August 2023, so the shares are not available through a broker. Anything you see quoted for ENOB elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before ENOB stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Enochian Biosciences, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Enochian Biosciences, Inc. do?
Enochian Biosciences, Inc. is a pre-clinical stage biotechnology company focused on developing innovative therapies for infectious diseases and cancer. The company's pipeline includes treatments and preventatives for HIV, HBV, influenza, coronavirus, and various solid tumors. Enochian operates through strategic partnerships with leading research institutions, leveraging their expertise to advance its pipeline.
What do analysts say about ENOB stock?
As of May 10, 2026, there is limited analyst coverage on Enochian Biosciences, Inc. (ENOB), likely due to its pre-clinical stage. Key valuation metrics are difficult to assess given the absence of revenue. Growth considerations center on the successful advancement of its pipeline through clinical trials and regulatory approvals.
What are the main risks for ENOB?
Enochian Biosciences faces several key risks inherent to pre-clinical stage biotechnology companies. These include the risk of failure to achieve positive results in clinical trials, regulatory setbacks and delays in the drug approval process, competition from larger pharmaceutical companies with greater resources, dependence on external funding to support operations, and potential intellectual property challenges.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The company is a pre-clinical stage biotechnology company, and its future success is highly dependent on the outcome of clinical trials and regulatory approvals.